Shopping Cart 0
Cart Subtotal
USD 0

Adocia SAS (ADOC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Adocia SAS (Adocia) is a biotechnology company that discovers and develops therapeutic proteins. The company provides products such as formulation of PDGF-BB for the treatment of diabetic foot ulcers. It offers novel insulin formulations for the treatment of diabetes and BioChaperone Lispro U100 and U200, ultra-rapid formulations of insulin analogs. Adocia develops HinsBet U100, a formulation of human insulin and a combination of slow-acting insulin glargine and rapid-acting insulin lispro. The company also develops a formulation of human insulin, HinsBet U500. Its BioChaperone is a proprietary technological platform developed from polymers, oligomers and small organic compounds, and others. It operates in the US and France. Adocia is headquartered in Lyon, France.

Adocia SAS (ADOC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Adocia SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Adocia SAS, Medical Devices Deals, 2012 to YTD 2018 9

Adocia SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adocia SAS, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Tonghua Dongbao Pharma Enters into Licensing Agreement with Adocia 11

Adocia Enters into Licensing Agreement with Centre National de la Recherche Scientifique 12

Equity Offering 13

Adocia Raises USD35 Million in Private Placement of Shares 13

Adocia Completes Partial Exercise Of Underwriter's Option For IPO For USD 36 Million 15

Adocia SAS-Key Competitors 16

Adocia SAS-Key Employees 17

Adocia SAS-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Recent Developments 19

Financial Announcements 19

Jul 18, 2018: Adocia presents first half 2018 financial results 19

Apr 16, 2018: Adocia Announces First Quarter 2018 Financial Results 21

Mar 19, 2018: ADOCIA Reports Financial Results For 2017 22

Oct 11, 2017: Adocia announces financial results for the third quarter 2017 24

Jul 19, 2017: Adocia Presents First Half 2017 Financial Results 26

Mar 07, 2017: ADOCIA announced its financial results for 2016 and its perspectives for 2017 28

Feb 14, 2017: Adocia announces its revenue and cash position for 2016 30

Corporate Communications 31

Jul 26, 2017: Adocia Announces Appointment of Dr. Stanislav Glezer as Chief Medical Officer 31

Legal and Regulatory 32

Oct 11, 2018: Adocia Informs about a Civil Action filed by Eli Lilly 32

Aug 30, 2018: Adocia announces update to second arbitration against Eli Lilly & Company 33

Aug 20, 2018: American Arbitration Association Panel Finds in Favor of Adocia in First Phase of Arbitration against Eli Lilly 34

Feb 06, 2018: Adocia Files Additional Arbitration Claims Against Eli Lilly & Company 35

Product News 36

01/05/2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes 36

Jan 04, 2018: Adocia Announces Expanded BioChaperone Product Portfolio beyond Diabetes 37

Clinical Trials 38

Apr 16, 2018: Adocia initiates First-in-Human Clinical Study of BioChaperone Pramlintide Insulin in people with type 1 diabetes 38

Jun 01, 2017: Adocia Launches First-in-Man Clinical Study of BioChaperone Glucagon BioChaperone Glucagon, a ready-to-use stable aqueous formulat 40

Other Significant Developments 41

Jan 19, 2017: Adocia announces the transformation of its business model to increase the value of its projects 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

Adocia SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adocia SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adocia SAS, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Adocia SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adocia SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adocia SAS, Deals By Therapy Area, 2012 to YTD 2018 9

Adocia SAS, Medical Devices Deals, 2012 to YTD 2018 10

Adocia SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Tonghua Dongbao Pharma Enters into Licensing Agreement with Adocia 12

Adocia Enters into Licensing Agreement with Centre National de la Recherche Scientifique 13

Adocia Raises USD35 Million in Private Placement of Shares 14

Adocia Completes Partial Exercise Of Underwriter's Option For IPO For USD 36 Million 16

Adocia SAS, Key Competitors 17

Adocia SAS, Key Employees 18

Adocia SAS, Subsidiaries 19

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Adocia SAS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Adocia SAS (Adocia) is a biotechnology company that discovers and develops therapeutic proteins. The company provides products such as formulation of PDGF-BB for the treatment of diabetic foot ulcers. It offers novel insulin formulations for the treatment of diabetes and BioChaperone Lispro U100 and U200, ultra-rapid formulations of insulin analogs. Adocia develops HinsBet U100, a formulation of human insulin and a combination of slow-acting insulin glargine and rapid-acting insulin lispro. The company also develops a formulation of human insulin, HinsBet U500. Its BioChaperone is a proprietary technological platform developed from polymers, oligomers and small organic compounds, and others. It operates in the US and France. Adocia is headquartered in Lyon, France.

Adocia SAS (ADOC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Adocia SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Adocia SAS, Medical Devices Deals, 2012 to YTD 2018 9

Adocia SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adocia SAS, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Tonghua Dongbao Pharma Enters into Licensing Agreement with Adocia 11

Adocia Enters into Licensing Agreement with Centre National de la Recherche Scientifique 12

Equity Offering 13

Adocia Raises USD35 Million in Private Placement of Shares 13

Adocia Completes Partial Exercise Of Underwriter's Option For IPO For USD 36 Million 15

Adocia SAS-Key Competitors 16

Adocia SAS-Key Employees 17

Adocia SAS-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Recent Developments 19

Financial Announcements 19

Jul 18, 2018: Adocia presents first half 2018 financial results 19

Apr 16, 2018: Adocia Announces First Quarter 2018 Financial Results 21

Mar 19, 2018: ADOCIA Reports Financial Results For 2017 22

Oct 11, 2017: Adocia announces financial results for the third quarter 2017 24

Jul 19, 2017: Adocia Presents First Half 2017 Financial Results 26

Mar 07, 2017: ADOCIA announced its financial results for 2016 and its perspectives for 2017 28

Feb 14, 2017: Adocia announces its revenue and cash position for 2016 30

Corporate Communications 31

Jul 26, 2017: Adocia Announces Appointment of Dr. Stanislav Glezer as Chief Medical Officer 31

Legal and Regulatory 32

Oct 11, 2018: Adocia Informs about a Civil Action filed by Eli Lilly 32

Aug 30, 2018: Adocia announces update to second arbitration against Eli Lilly & Company 33

Aug 20, 2018: American Arbitration Association Panel Finds in Favor of Adocia in First Phase of Arbitration against Eli Lilly 34

Feb 06, 2018: Adocia Files Additional Arbitration Claims Against Eli Lilly & Company 35

Product News 36

01/05/2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes 36

Jan 04, 2018: Adocia Announces Expanded BioChaperone Product Portfolio beyond Diabetes 37

Clinical Trials 38

Apr 16, 2018: Adocia initiates First-in-Human Clinical Study of BioChaperone Pramlintide Insulin in people with type 1 diabetes 38

Jun 01, 2017: Adocia Launches First-in-Man Clinical Study of BioChaperone Glucagon BioChaperone Glucagon, a ready-to-use stable aqueous formulat 40

Other Significant Developments 41

Jan 19, 2017: Adocia announces the transformation of its business model to increase the value of its projects 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

Adocia SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adocia SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adocia SAS, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Adocia SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adocia SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adocia SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adocia SAS, Deals By Therapy Area, 2012 to YTD 2018 9

Adocia SAS, Medical Devices Deals, 2012 to YTD 2018 10

Adocia SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Tonghua Dongbao Pharma Enters into Licensing Agreement with Adocia 12

Adocia Enters into Licensing Agreement with Centre National de la Recherche Scientifique 13

Adocia Raises USD35 Million in Private Placement of Shares 14

Adocia Completes Partial Exercise Of Underwriter's Option For IPO For USD 36 Million 16

Adocia SAS, Key Competitors 17

Adocia SAS, Key Employees 18

Adocia SAS, Subsidiaries 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Adocia SAS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.